Research graph
References from Recent advances in allergen immunotherapy. Local targets link to admitted publications; unresolved targets remain external evidence.
Patterns and trends in asthma incidence rates in main Asian and Western countries and their prediction to 2030
10.1016/j.pccm.2024.08.004 · 2024 · External reference
EAACI guidelines on environmental science for allergy and asthma: The impact of short-term exposure to outdoor air pollutants on asthma-related outcomes and recommendations for mitigation measures
10.1111/all.16103 · 2024 · External reference
Involvement and therapeutic implications of airway epithelial barrier dysfunction in type 2 inflammation of asthma
10.1097/cm9.0000000000001983 · 2022 · External reference
Hot topics in allergen immunotherapy, 2023: Current status and future perspective
10.1111/all.15945 · 2024 · External reference
One hundred and ten years of allergen immunotherapy: A journey from empiric observation to evidence
10.1111/all.15023 · 2022 · External reference
Allergen immunotherapy: Past, present and future
10.1038/s41577-022-00786-1 · 2023 · External reference
Allergen immunotherapy and biologics in respiratory allergy: Friends or foes?
10.1097/aci.0000000000000707 · 2021 · External reference
TH2 lymphocytes from atopic patients treated with immunotherapy undergo rapid apoptosis after culture with specific allergens
10.1067/mai.2001.112263 · 2001 · External reference
Sublingual immunotherapy for asthma: Affects T-cells but does not impact basophil activation
10.1089/ped.2014.0328 · 2014 · External reference
Changes in CD4+CD25+FoxP3+ regulatory T cells and serum cytokines in sublingual and subcutaneous immunotherapy in allergic rhinitis with or without asthma
10.1159/000503143 · 2020 · External reference
Specific immunoglobulin G4 correlates with Th2 cytokine reduction in patients with allergic asthma treated by Dermatophagoides pteronyssinus subcutaneous immunotherapy
10.1016/j.waojou.2022.100715 · 2023 · External reference
Both allergen-specific CD4 and CD8 type 2 T cells decreased in asthmatic children with immunotherapy
10.1034/j.1399-3038.2003.00054.x · 2003 · External reference
Peripheral blood mononuclear cell transcriptome profile in a clinical trial with subcutaneous, grass pollen allergoid immunotherapy
10.1111/cea.14432 · 2024 · External reference
Der p 1-specific regulatory T-cell response during house dust mite allergen immunotherapy
10.1111/all.13684 · 2019 · External reference
Increased expression of allergen-induced in vitro interleukin-10 and interleukin-18 mRNA in peripheral blood mononuclear cells of allergic rhinitis patients after specific immunotherapy
10.1111/j.1365-2222.2004.01823.x · 2004 · External reference
Bee venom ameliorates ovalbumin induced allergic asthma via modulating CD4+CD25+ regulatory T cells in mice
10.1016/j.cyto.2012.10.005 · 2013 · External reference
House dust mite sublingual immunotherapy: The role for transforming growth factor-beta and functional regulatory T cells
10.1164/rccm.200905-0686oc · 2009 · External reference
Role of IL-35 in sublingual allergen immunotherapy
10.1016/j.jaci.2018.06.041 · 2019 · External reference
Roles of follicular helper and regulatory T cells in allergic diseases and allergen immunotherapy
10.1111/all.14639 · 2021 · External reference
Foxp3+ follicular regulatory T cells control the germinal center response
10.1038/nm.2425 · 2011 · External reference
Immunologic mechanisms of a short-course of Lolium perenne peptide immunotherapy: A randomized, double-blind, placebo-controlled trial
10.1016/j.jaci.2019.02.023 · 2019 · External reference
Allergen immunotherapy improves defective follicular regulatory T cells in patients with allergic rhinitis
10.1016/j.jaci.2019.02.008 · 2019 · External reference
B regulatory cells in allergy
10.1111/imr.12937 · 2021 · External reference
CD24(hi)CD27(+) B cells from patients with allergic asthma have impaired regulatory activity in response to lipopolysaccharide
10.1111/cea.12238 · 2014 · External reference
IgG4 production is confined to human IL-10-producing regulatory B cells that suppress antigen-specific immune responses
10.1016/j.jaci.2013.01.014 · 2013 · External reference
Role of Der p 1-specific B cells in immune tolerance during 2 years of house dust mite-specific immunotherapy
10.1016/j.jaci.2018.10.061 · 2019 · External reference
The role of regulatory B cells in allergen immunotherapy
10.1097/aci.0000000000000400 · 2017 · External reference
Role of regulatory B cells in immune tolerance to allergens and beyond
10.1016/j.jaci.2016.07.006 · 2016 · External reference
EAACI allergen immunotherapy user’s guide
10.1111/pai.13189 · 2020 · External reference
Changes in markers associated with dendritic cells driving the differentiation of either TH2 cells or regulatory T cells correlate with clinical benefit during allergen immunotherapy
10.1016/j.jaci.2015.09.015 · 2016 · External reference
Trained immunity and tolerance in innate lymphoid cells, monocytes, and dendritic cells during allergen-specific immunotherapy
10.1016/j.jaci.2020.08.042 · 2021 · External reference
An Interleukin-33-mast cell-Interleukin-2 axis suppresses papain-induced allergic inflammation by promoting regulatory T cell numbers
10.1016/j.immuni.2015.06.021 · 2015 · External reference
Seasonal increases in peripheral innate lymphoid type 2 cells are inhibited by subcutaneous grass pollen immunotherapy
10.1016/j.jaci.2014.07.029 · 2014 · External reference
Induction of IL-10-producing type 2 innate lymphoid cells by allergen immunotherapy is associated with clinical response
10.1016/j.immuni.2020.12.013 · 2021 · External reference
Natural killer cells in the lung: Potential role in asthma and virus-induced exacerbation?
10.1183/16000617.0036-2023 · 2023 · External reference
Production of interleukin-12 by monocytes and interferon-gamma by natural killer cells in allergic patients during rush immunotherapy
10.1016/s1081-1206(10)60936-2 · 2006 · External reference
Allergen-specific immunotherapy induces regulatory T cells in an atopic dermatitis mouse model
10.1111/all.13465 · 2018 · External reference
Activation of invariant natural killer T cells in regional lymph nodes as new antigen-specific immunotherapy via induction of interleukin-21 and interferon-γ
10.1111/cei.12399 · 2014 · External reference
Invariant natural killer cells change after an oral allergy desensitization protocol for cow’s milk
10.1111/cea.12975 · 2017 · External reference
Allergoid-mannan conjugates reprogram monocytes into tolerogenic dendritic cells via epigenetic and metabolic rewiring
10.1016/j.jaci.2021.06.012 · 2022 · External reference
From trained immunity in allergy to trained immunity-based allergen vaccines
10.1111/cea.14261 · 2023 · External reference
Grass pollen immunotherapy decreases the number of mast cells in the skin
10.1046/j.1365-2222.1999.00678.x · 1999 · External reference
IL-9 and c-Kit+ mast cells in allergic rhinitis during seasonal allergen exposure: Effect of immunotherapy
10.1016/j.jaci.2005.03.011 · 2005 · External reference
Mast cell desensitization in allergen immunotherapy
10.3389/falgy.2022.898494 · 2022 · External reference
Early suppression of basophil activation during allergen-specific immunotherapy by histamine receptor 2
10.1016/j.jaci.2012.04.039 · 2012 · External reference
Grass pollen immunotherapy inhibits seasonal increases in basophils and eosinophils in the nasal epithelium
10.1046/j.1365-2222.2001.01231.x · 2001 · External reference
The effect of immunotherapy on bronchial hyperresponsiveness and eosinophil cationic protein in pollen-allergic patients
10.1016/0091-6749(88)90021-8 · 1988 · External reference
Allergy immunotherapy restores airway epithelial barrier dysfunction through suppressing IL-25-induced endoplasmic reticulum stress in asthma
10.1038/s41598-018-26221-x · 2018 · External reference
Allergen immunotherapy effectively reduces the risk of exacerbations and lower respiratory tract infections in both seasonal and perennial allergic asthma: A nationwide epidemiological study
10.1183/13993003.00446-2022 · 2022 · External reference
Allergen immunotherapy enhances airway epithelial antiviral immunity in patients with allergic asthma (VITAL Study): A double-blind randomized controlled trial
10.1164/rccm.202209-1708oc · 2023 · External reference
Birch pollen-specific subcutaneous immunotherapy reduces ILC2 frequency but does not suppress IL-33 in mice
10.1111/cea.13254 · 2018 · External reference
Advancing precision medicine in asthma: Evolution of treatment outcomes
10.1016/j.jaci.2023.07.009 · 2023 · External reference
The role of allergen-specific IgE, IgG and IgA in allergic disease
10.1111/all.14908 · 2021 · External reference
Nasal allergen-neutralizing IgG4 antibodies block IgE-mediated responses: Novel biomarker of subcutaneous grass pollen immunotherapy
10.1016/j.jaci.2018.09.039 · 2019 · External reference
Immunological comparison of allergen immunotherapy tablet treatment and subcutaneous immunotherapy against grass allergy
10.1111/cea.12241 · 2014 · External reference
Diverse immune mechanisms of allergen immunotherapy for allergic rhinitis with and without asthma
10.1016/j.jaci.2022.01.016 · 2022 · External reference
On the role of antibody affinity and avidity in the IgE-mediated allergic response
10.1111/all.16248 · 2025 · External reference
Grass pollen immunotherapy induces an allergen-specific IgA2 antibody response associated with mucosal TGF-beta expression
10.4049/jimmunol.178.7.4658 · 2007 · External reference
Subcutaneous allergen-specific immunotherapy for allergic rhinitis: Divergent IgA responses in nasal mucosa and blood with validation of B cell class-switching in lymph nodes and blood
10.1002/clt2.70097 · 2025 · External reference
Allergen-specific immunotherapy boosts allergen-specific IgD production in house dust mite-sensitized asthmatic patients
10.1111/all.14133 · 2020 · External reference
“Molecular extracts” for allergy diagnostics and therapy
10.1111/pai.13001 · 2019 · External reference
Molecular allergology and its impact in specific allergy diagnosis and therapy
10.1111/all.14969 · 2021 · External reference
Past, present, and future of allergen immunotherapy vaccines
10.1111/all.14300 · 2021 · External reference
Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis
10.1016/j.jaci.2008.09.017 · 2008 · External reference
Double-blind, randomized, placebo-controlled trial of allergen-specific immunotherapy with the major allergen Alt a 1
10.1016/j.jaci.2019.02.029 · 2019 · External reference
Specific subcutaneous immunotherapy with recombinant grass pollen allergens: First randomized dose-ranging safety study
10.1111/j.1365-2222.2012.03971.x · 2012 · External reference
Immunotherapy with recombinant Alt a 1 suppresses allergic asthma and influences T follicular cells and regulatory B cells in mice
2021 · External reference
Mechanisms underlying allergy vaccination with recombinant hypoallergenic allergen derivatives
10.1016/j.vaccine.2011.11.011 · 2012 · External reference
Recombinant allergy vaccines based on allergen-derived B cell epitopes
10.1016/j.imlet.2017.04.015 · 2017 · External reference
Skin test evaluation of a novel peptide carrier-based vaccine, BM32, in grass pollen-allergic patients
10.1016/j.jaci.2015.03.034 · 2015 · External reference
Safety and efficacy of immunotherapy with the recombinant B-cell epitope-based grass pollen vaccine BM32
10.1016/j.jaci.2017.09.052 · 2018 · External reference
Two years of treatment with the recombinant grass pollen allergy vaccine BM32 induces a continuously increasing allergen-specific IgG4 response
10.1016/j.ebiom.2019.11.006 · 2019 · External reference
Allergen immunotherapy with the hypoallergenic B-cell epitope-based vaccine BM32 modifies IL-10- and IL-5-secreting T cells
10.1111/all.13996 · 2020 · External reference
Virus-like particles displaying major house dust mite allergen Der p 2 for prophylactic allergen immunotherapy
10.1111/all.14096 · 2020 · External reference
Genetically engineered fusion of allergen and viral-like particle induces a more effective allergen-specific immune response than a combination of them
10.1007/s00253-020-11012-0 · 2021 · External reference
Prevention of allergy by virus-like nanoparticles (VNP) delivering shielded versions of major allergens in a humanized murine allergy model
10.1111/all.13573 · 2019 · External reference
Development of rice-seed-based oral allergy vaccines containing hypoallergenic Japanese cedar pollen allergen derivatives for immunotherapy
10.1021/acs.jafc.9b05421 · 2019 · External reference
Long-term oral administration of transgenic rice containing cedar pollen T-cell epitopes potentially improves medication- and allergy-related quality-of-life scores
10.2500/aap.2021.42.210011 · 2021 · External reference
Prophylactic and therapeutic effects of oral immunotherapy on birch pollen-induced allergic conjunctivitis in mice with a rice-based edible vaccine expressing a hypoallergenic birch pollen allergen
10.3390/cells10123361 · 2021 · External reference
Treating cat allergy with monoclonal IgG antibodies that bind allergen and prevent IgE engagement
10.1038/s41467-018-03636-8 · 2018 · External reference
Patient-centered digital biomarkers for allergic respiratory diseases and asthma: The ARIA-EAACI approach - ARIA-EAACI task force report
10.1111/all.15740 · 2023 · External reference
Increase of regulatory T cells and the ratio of specific IgE to total IgE are candidates for response monitoring or prognostic biomarkers in 2-year sublingual immunotherapy (SLIT) for Japanese cedar pollinosis
10.1016/j.clim.2010.12.022 · 2011 · External reference
Impact of IgG subclass on molecular properties of monoclonal antibodies
10.1080/19420862.2021.1993768 · 2021 · External reference
Induction of IgG2 and IgG4 B-cell memory following sublingual immunotherapy for ryegrass pollen allergy
10.1111/all.14073 · 2020 · External reference
Coordinated IgG2 and IgE responses as a marker of allergen immunotherapy efficacy
10.1111/all.15107 · 2022 · External reference
A long-term follow-up study of hyposensitization with immunoblotting
10.1016/0091-6749(90)90043-4 · 1990 · External reference
Quantitative IgE- and IgG-subclass responses during and after long-term ragweed immunotherapy
10.1016/0091-6749(92)90318-v · 1992 · External reference
The role of IgG1 and IgG4 as dominant IgE-blocking antibodies shifts during allergen immunotherapy
10.1016/j.jaci.2023.01.005 · 2023 · External reference
The functional IgE-blocking factor induced by allergen-specific immunotherapy correlates with IgG4 antibodies and a decrease of symptoms in house dust mite-allergic children
10.1159/000444391 · 2016 · External reference
Biomarkers for monitoring clinical efficacy of allergen immunotherapy for allergic rhinoconjunctivitis and allergic asthma: An EAACI Position Paper
10.1111/all.13138 · 2017 · External reference
The IgE-facilitated allergen binding (FAB) assay: Validation of a novel flow-cytometric based method for the detection of inhibitory antibody responses
10.1016/j.jim.2006.09.004 · 2006 · External reference
Functional rather than immunoreactive levels of IgG4 correlate closely with clinical response to grass pollen immunotherapy
10.1111/j.1398-9995.2011.02745.x · 2012 · External reference
Functional and immunoreactive levels of IgG4 correlate with clinical responses during the maintenance phase of house dust mite immunotherapy
10.4049/jimmunol.1701690 · 2018 · External reference
Suppression function against environmental dust exposure after Dermatophagoides pteronyssinus immunotherapy is associated with production of specific and cross-reactive immunoglobulin G4
10.1111/cea.14088 · 2022 · External reference
Basophil activation test: Mechanisms and considerations for use in clinical trials and clinical practice
10.1111/all.14747 · 2021 · External reference
Expression of CD203c and CD63 in human basophils: Relationship to differential regulation of piecemeal and anaphylactic degranulation processes
10.1111/j.1365-2222.2010.03572.x · 2010 · External reference
Immunotherapy with a modified birch pollen extract in allergic rhinoconjunctivitis: Clinical and immunological effects
10.1111/j.1365-2222.2009.03379.x · 2009 · External reference
Initial immunological changes as predictors for house dust mite immunotherapy response
10.1111/cea.12578 · 2015 · External reference
Synchronous immune alterations mirror clinical response during allergen immunotherapy
10.1016/j.jaci.2017.09.041 · 2018 · External reference
Basophil activation test: A diagnostic, predictive and monitoring assay for allergen immunotherapy
10.1111/all.14585 · 2021 · External reference
Which patients with asthma are most likely to benefit from allergen immunotherapy?
10.1016/j.jaci.2022.01.011 · 2022 · External reference
Sublingual grass pollen immunotherapy is associated with increases in sublingual Foxp3-expressing cells and elevated allergen-specific immunoglobulin G4, immunoglobulin A and serum inhibitory activity for immunoglobulin E-facilitated allergen binding to B cells
10.1111/j.1365-2222.2010.03462.x · 2010 · External reference
High-dose bee venom exposure induces similar tolerogenic B-cell responses in allergic patients and healthy beekeepers
10.1111/all.12966 · 2017 · External reference
A regulatory dendritic cell signature correlates with the clinical efficacy of allergen-specific sublingual immunotherapy
10.1016/j.jaci.2012.02.014 · 2012 · External reference
Allergen-specific immunotherapy modulates the balance of circulating Tfh and Tfr cells
10.1016/j.jaci.2017.04.032 · 2018 · External reference
Effect of grass pollen immunotherapy on clinical and local immune response to nasal allergen challenge
10.1111/all.12608 · 2015 · External reference
Enhanced benefit from house dust mite immunotherapy in subjects with low serum levels of LILRA5 or CCL25
10.1111/all.16386 · 2025 · External reference
In vivo diagnosis of allergic diseases--allergen provocation tests
10.1111/all.12586 · 2015 · External reference
EAACI guidelines on allergen immunotherapy: Prevention of allergy
10.1111/pai.12807 · 2017 · External reference
Clinical practice recommendations for allergen-specific immunotherapy in children: The Italian consensus report
10.1186/s13052-016-0315-y · 2017 · External reference
Standardization of clinical outcomes used in allergen immunotherapy in allergic asthma: An EAACI position paper
10.1111/all.15817 · 2023 · External reference
EAACI Guidelines on Allergen Immunotherapy: House dust mite-driven allergic asthma
10.1111/all.13749 · 2019 · External reference
Small airways in asthma: Pathophysiology, identification and management
10.1016/j.pccm.2023.07.002 · 2023 · External reference
Effectiveness of sublingual immunotherapy in the treatment of HDM-induced nasobronchial allergies: A 3-year randomized case-control study from Kashmir
10.3389/fimmu.2021.723814 · 2021 · External reference
A 5-Year open-label follow-up of a randomized double-blind placebo-controlled trial of intralymphatic immunotherapy for birch and grass allergy reveals long-term beneficial effects
10.18176/jiaci.0832 · 2023 · External reference
Efficacy and safety of HDM SLIT tablet in Japanese adults with allergic asthma
10.1016/j.jaip.2019.09.002 · 2020 · External reference
Compliance, efficacy, and safety of subcutaneous and sublingual immunotherapy in children with allergic rhinitis
10.1111/pai.13332 · 2020 · External reference
Long-term efficacy of house dust mite sublingual immunotherapy on clinical and pulmonary function in patients with asthma and allergic rhinitis
2024 · External reference
Allergen provocation tests in respiratory research: Building on 50 years of experience
10.1183/13993003.02782-2021 · 2022 · External reference
Allergen exposure chambers: Implementation in clinical trials in allergen immunotherapy
10.1186/s13601-020-00336-9 · 2020 · External reference
Innovative delivery systems for epicutaneous immunotherapy
2023 · External reference
Intralymphatic immunotherapy: A status update
10.1016/j.anai.2023.11.030 · 2024 · External reference
Intralymphatic immunotherapy
10.1097/aci.0b013e3283310ff7 · 2009 · External reference
Efficacy of subcutaneous, sublingual and oral immunotherapy for allergens: A comparative study
10.1111/imm.13898 · 2025 · External reference
Intralymphatic immunotherapy: Update and unmet needs
10.1159/000493647 · 2018 · External reference
Intralymphatic immunotherapy with 2 concomitant allergens, birch and grass: A randomized, double-blind, placebo-controlled trial
10.1016/j.jaci.2018.05.030 · 2018 · External reference
Intralymphatic immunotherapy in pollen-allergic young adults with rhinoconjunctivitis and mild asthma: A randomized trial
10.1016/j.jaci.2019.11.017 · 2020 · External reference
Efficacy and safety of intralymphatic immunotherapy for allergic rhinitis: An overview of systematic reviews and meta analyses
10.3389/fmed.2025.1709531 · 2025 · External reference
Evaluation of intralymphatic immunotherapy in allergic rhinitis patients: A systematic review and meta-analysis
10.1155/2023/9377518 · 2023 · External reference
Intratonsillar immunotherapy: A convenient and effective alternative to subcutaneous immunotherapy for allergic rhinitis
2025 · External reference
Efficacy and safety of intratonsillar immunotherapy for allergic rhinitis: A randomized, double-blind, placebo-controlled clinical trial
10.1016/j.anai.2023.10.029 · 2023 · External reference
Liver-targeted allergen immunotherapy rapidly and safely induces antigen-specific tolerance to treat allergic airway disease in mice
10.1126/scitranslmed.adl0406 · 2025 · External reference
A randomized trial of subcutaneous allergy immunotherapy in inner-city children with asthma less than 4 years of age
10.1016/j.anai.2020.12.016 · 2021 · External reference
Primary prevention of asthma in high-risk children using HDM SLIT: Assessment at age 6 years
10.1016/j.jaci.2020.01.048 · 2020 · External reference
Results from the 5-year SQ grass sublingual immunotherapy tablet asthma prevention (GAP) trial in children with grass pollen allergy
10.1016/j.jaci.2017.06.014 · 2018 · External reference
Efficacy of a house dust mite sublingual allergen immunotherapy tablet in adults with allergic asthma: A randomized clinical trial
10.1001/jama.2016.3964 · 2016 · External reference
House dust mite sublingual immunotherapy is safe in patients with mild-to-moderate, persistent asthma: A clinical trial
10.1111/all.12791 · 2016 · External reference
Efficacy analysis of three-year subcutaneous SQ-standardized specific immunotherapy in house dust mite-allergic children with asthma
10.3892/etm.2014.1469 · 2014 · External reference
SQ HDM SLIT-tablet (ALK) in treatment of asthma – post hoc results from a randomized trial
10.1016/j.rmed.2014.07.017 · 2014 · External reference
Development of cockroach immunotherapy by the inner-city asthma consortium
10.1016/j.jaci.2013.08.047 · 2014 · External reference
Immunotherapy with grass pollen tablets reduces medication dispensing for allergic rhinitis and asthma: A retrospective database study in France
10.1111/all.13705 · 2019 · External reference
Long-term real-world effectiveness of allergy immunotherapy in patients with allergic rhinitis and asthma: Results from the REACT study, a retrospective cohort study
2022 · External reference
Real-world evidence of subcutaneous allergoid immunotherapy in house dust mite-induced allergic rhinitis and asthma
10.1111/all.14240 · 2020 · External reference
Real-world benefits of allergen immunotherapy for birch pollen-associated allergic rhinitis and asthma
10.1111/all.13598 · 2019 · External reference
Effectiveness and safety of a glutaraldehyde-modified, L-tyrosine-adsorbed and monophosphoryl lipid A-Adjuvanted allergen immunotherapy in patients with allergic asthma sensitized to olive pollen: A retrospective, controlled real-world study
10.1016/j.waojou.2020.100487 · 2020 · External reference
Efficacy of allergen immunotherapy for allergic asthma in real world practice
10.4168/aair.2020.12.1.99 · 2020 · External reference
Impact of liquid sublingual immunotherapy on asthma onset and progression in patients with allergic rhinitis: A nationwide population-based study (EfficAPSI study)
2024 · External reference
The moderating role of allergy immunotherapy in asthma progression: Results of a population-based cohort study
10.1111/all.14020 · 2020 · External reference
House dust mite SCIT reduces asthma risk and significantly improves long-term rhinitis and asthma control-A RWE study
10.1111/all.16052 · 2024 · External reference
Sublingual immunotherapy provides long-term relief in allergic rhinitis and reduces the risk of asthma: A retrospective, real-world database analysis
10.1111/all.13213 · 2018 · External reference
Long-term effects of pollen allergoid tyrosine-adsorbed subcutaneous immunotherapy on allergic rhinitis and asthma
10.1111/cea.14444 · 2024 · External reference
House dust mite immunotherapy: A real-world, prescription data-based analysis
10.1002/clt2.12382 · 2024 · External reference
Update on pathomechanisms and treatments in allergic rhinitis
10.1111/all.15454 · 2022 · External reference
Efficacy and safety of sublingual versus subcutaneous immunotherapy in children with allergic rhinitis: A systematic review and meta-analysis
10.3389/fimmu.2023.1274241 · 2023 · External reference
Chinese guideline on allergen immunotherapy for allergic rhinitis: The 2022 update
10.4168/aair.2022.14.6.604 · 2022 · External reference
EAACI guidelines on allergen immunotherapy: Allergic rhinoconjunctivitis
10.1111/all.13317 · 2017 · External reference
Efficacy of different allergen-specific immunotherapies for the treatment of allergic rhinitis in children and adults: An umbrella review
10.3389/fimmu.2025.1658826 · 2025 · External reference
Efficacy and safety of SQ house dust mite sublingual immunotherapy-tablet (12 SQ-HDM) in children with allergic rhinitis/rhinoconjunctivitis with or without asthma (MT-12): A randomised, double-blind, placebo-controlled, phase III trial
2024 · External reference
The SQ tree sublingual immunotherapy tablet is effective and well tolerated in children-A pivotal phase III trial
10.1111/all.16363 · 2024 · External reference
Short-course subcutaneous treatment with birch pollen allergoids greatly improves symptom and medication scores in birch allergy
10.1111/all.16387 · 2024 · External reference
Disease-modifying effect of Japanese cedar pollen sublingual immunotherapy tablets
10.1016/j.jaip.2021.06.060 · 2021 · External reference
Real-world, long-term effectiveness of allergy immunotherapy in allergic rhinitis: Subgroup analyses of the REACT study
10.1016/j.jaci.2023.02.024 · 2023 · External reference
Next-generation allergic rhinitis and its impact on asthma (ARIA) guidelines for allergic rhinitis based on grading of recommendations assessment, development and evaluation (GRADE) and real-world evidence
10.1016/j.jaci.2019.06.049 · 2019 · External reference
Real-world study: Drug reduction in children with allergic rhinitis and asthma receiving immunotherapy
10.2217/imt-2022-0215 · 2023 · External reference
Allergen immunotherapy for atopic dermatitis: Systematic review and meta-analysis of benefits and harms
10.1016/j.jaci.2022.09.020 · 2022 · External reference
The effectiveness of allergen immunotherapy in adult patients with atopic dermatitis allergic to house dust mites
10.3390/medicina59010015 · 2022 · External reference
Efficacy of house dust mite sublingual immunotherapy in patients with atopic dermatitis: A randomized, double-Blind, placebo-controlled trial
10.1016/j.jaip.2021.10.060 · 2021 · External reference
What has changed with subcutaneous immunotherapy against house dust mites? Eight-year, single-center real-world data
10.5415/apallergy.0000000000000202 · 2025 · External reference
Debates in allergy medicine: Specific immunotherapy efficiency in children with atopic dermatitis
10.1186/s40413-016-0106-3 · 2016 · External reference
Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE- and Institute of Medicine-based recommendations
10.1016/j.anai.2023.11.009 · 2023 · External reference
Allergen immunotherapy and dupilumab in atopic dermatitis: Clinical efficacy and disparities in immunological indicators
10.1016/j.waojou.2025.101043 · 2025 · External reference
Atopic dermatitis occurrence and progression and allergen immunotherapy: A real-world, retrospective cohort study in Germany
10.1016/j.waojou.2025.101090 · 2025 · External reference
Recent Advances in oral immunotherapy for food allergies
10.1007/s12016-025-09108-4 · 2025 · External reference
Treatment of multi-food allergy with omalizumab compared to omalizumab-facilitated multi-allergen OIT
10.1016/j.jaci.2024.12.1022 · 2025 · External reference
Venom allergen immunotherapy in children: Short-term efficacy and impact on quality of life
10.1016/j.anai.2025.02.018 · 2025 · External reference
From gene identifications to therapeutic targets for asthma: Focus on great potentials of TSLP, ORMDL3, and GSDMB
10.1016/j.pccm.2023.08.001 · 2023 · External reference
Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma
10.1016/j.jaci.2009.11.022 · 2010 · External reference
Children with severe asthma can start allergen immunotherapy after controlling asthma with omalizumab: A case series from Poland
10.5114/aoms.2015.48546 · 2015 · External reference
Combination of omalizumab with allergen immunotherapy versus immunotherapy alone for allergic diseases: A meta-analysis of randomized controlled trials
10.1002/alr.23268 · 2024 · External reference
Efficacy of a house dust mite sublingual immunotherapy tablet as add-on dupilumab in asthma with rhinitis
10.1016/j.alit.2022.05.010 · 2022 · External reference
Effects of combination treatment with tezepelumab and allergen immunotherapy on nasal responses to allergen: A randomized controlled trial
10.1016/j.jaci.2022.08.029 · 2023 · External reference
Combination of allergen-specific immunotherapy with biologics in severe asthma: Counterintuitive or rational?
10.1016/j.jaip.2025.05.003 · 2025 · External reference
Pediatric allergen immunotherapy in the United States: Current practice, safety, and unmet needs for long-term and preventive outcomes
10.2500/aap.2025.46.250058 · 2025 · External reference
Role of allergen immunotherapy and biologics in allergic diseases
10.1016/j.coi.2024.102494 · 2024 · External reference
Standardized allergen extracts for allergen immunotherapy
10.2500/aap.2022.43.220015 · 2022 · External reference
